Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report report published on Thursday morning. The brokerage issued a strong-buy rating on the stock.

Separately, Truist Financial cut their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $22.00.

Fresenius Medical Care Stock Up 0.2 %

Shares of NYSE FMS opened at $19.39 on Thursday. Fresenius Medical Care has a 12 month low of $16.37 and a 12 month high of $24.48. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $11.38 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 1.03 and a beta of 0.90. The business has a 50-day moving average of $19.30 and a 200-day moving average of $19.90.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting the consensus estimate of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. Sell-side analysts expect that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV boosted its stake in Fresenius Medical Care by 4.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock worth $278,000 after buying an additional 624 shares in the last quarter. Signaturefd LLC boosted its stake in Fresenius Medical Care by 8.4% in the second quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after buying an additional 672 shares in the last quarter. GAMMA Investing LLC lifted its position in Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after purchasing an additional 758 shares during the last quarter. Ritholtz Wealth Management lifted its position in Fresenius Medical Care by 2.5% in the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company’s stock valued at $704,000 after purchasing an additional 895 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after purchasing an additional 1,128 shares during the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.